- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01614210
Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance (POWER PIINC)
Descripción general del estudio
Estado
Intervención / Tratamiento
Descripción detallada
Patients who are eligible (newly diagnosed hormone positive clinical stage 1 or 2 breast cancer) will be approached about the study. If they sign informed consent a prescription for 21 doses of Tamoxifen will be provided. The patient's surgery will be scheduled at a time convenient for the patient and the surgeon. Once the surgery has been scheduled, a medication calendar will be completed that allows the patient to take tamoxifen for 7 days preoperatively with the 7th dose of tamoxifen to coincide with the day before surgery. The patient will continue to take tamoxifen for 2 weeks (14 days) after surgery. Patients will then proceed along normal treatment guidelines. For those needing chemotherapy or radiation therapy, we recommend the long term endocrine therapy start at the conclusion of chemo and/or radiation treatments. For those not going on to any additional therapy, the prescription for endocrine therapy will be written at the initial post-operative visit.
Unstained slides from the formalin-fixed, paraffin-embedded tissue blocks from the patient's breast tissue from which the original diagnosis of breast cancer was made by H&E will be stained for Ki67. After endocrine therapy and subsequent resection, carcinoma will be confirmed by the participating pathologist on H&E, and Ki67 will be performed on unstained slides from a representative tissue block containing invasive carcinoma. The pathologist will circle a designated area of tumor on the H&E slide and both the H&E and immunostained (Ki67) slides will be scanned in a digital imaging device (Aperio XT Scanscope), which quantitatively analyzes the tumor designated by the pathologist with image analysis algorithms. The algorithm accurately detects regions of interest and distinguishes cells and sub-cellular objects within these target regions. It determines morphology and expression profiles per individual cell or cell compartment. For Ki67 analysis, a nuclear Immunohistochemistry (IHC) algorithm will be used.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Huntsman Cancer Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Age > 18 years old
- Diagnosed with hormone receptor positive invasive breast cancer (estrogen receptor (ER) or progesterone receptor (PR) or both >1%) by core needle biopsy
- Clinical American Joint Committee on Cancer (AJCC) 7th edition Stage 1 or 2
- Candidate for surgical therapy
- Eastern Cooperative Oncology Group (ECOG) performance status 0,1, or 2
- No chemotherapy or endocrine therapy for breast cancer in last 5 years
- Paraffin fixed core needle tissue block, or biopsy punch available for central analysis for proliferative markers
- Not pregnant or lactating and practicing adequate birth control if premenopausal
- Able and willing to provide informed consent
Exclusion Criteria:
- Prior personal history of uterine cancer
- Prior personal history of stroke or deep vein thrombosis (DVT)
- Current therapy with strong CYP2D6 inhibitors The following medications should not be administered with tamoxifen (21 day treatment period) and will need to be stopped for the designated period of time prior to starting the study tamoxifen.
No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage 0, I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years
Fluoxetine - should be discontinued 30 days prior to starting tamoxifen Paroxetine - should be discontinued 5 days prior to starting tamoxifen Sertraline - should be discontinued 5 days prior to starting tamoxifen Bupropion - should be discontinued 5 days prior to starting tamoxifen
- Concurrent coumarin-type anticoagulation therapy
- Any other contraindications to tamoxifen therapy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: All patients
All patients enrolled in the study.
|
All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
Breast cancer surgery
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change in Ki67 Expression in Tumors
Periodo de tiempo: 7 days
|
Demonstrate a significant change in Ki67 expression in tumors with 7 days of pre-surgical tamoxifen.
|
7 days
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change in FACT-ES Symptom Scores
Periodo de tiempo: 18 months
|
Patients were given the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) quality of life assessment at baseline (prior to tamoxifen administration) and again 18 months following breast surgery to assess quality of life.
The difference in total score from baseline to 18 months was calculated.
The FACT-ES total score ranges from 0-180, with higher scores indicating higher quality of life.
|
18 months
|
Number of Participants With Long Term Endocrine Therapy Adherence
Periodo de tiempo: 18 months
|
For the patient population on this study, endocrine therapy was indicated for 5 years post-surgery according to the current standard of care recommendations for hormone positive breast cancer.
Endocrine therapy was prescribed as standard of care as appropriate for each patient's situation.
At 18 months post-surgery, patients were evaluated to determine if they were taking their endocrine therapy as prescribed.
|
18 months
|
Correlation Between Changes in Ki67 and Symptoms
Periodo de tiempo: 7 days
|
Evaluate correlation between changes in Ki67 expression and symptom scores.
Differences between changes in FACT-ES total score were correlated with changes in Ki67 expression using a the Spearman correlation method and results are expressed as the correlation coefficient.
|
7 days
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change in FACT-ES Symptom Scores
Periodo de tiempo: 7 days
|
Patients were given the Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) quality of life assessment at baseline (prior to tamoxifen administration) and again 7 days following start of tamoxifen to assess quality of life while on tamoxifen.
The difference in total score from baseline to 7 days was calculated.
The FACT-ES total score ranges from 0-180, with higher scores indicating higher quality of life.
|
7 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Leigh Neumayer, MD, Huntsman Cancer Institute
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Efectos fisiológicos de las drogas
- Agentes antineoplásicos
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Agentes Antineoplásicos Hormonales
- Antagonistas de hormonas
- Agentes de conservación de la densidad ósea
- Antagonistas de estrógeno
- Moduladores selectivos del receptor de estrógeno
- Moduladores del receptor de estrógeno
- Tamoxifeno
Otros números de identificación del estudio
- HCI57098
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Tamoxifen
-
Institut Cancerologie de l'OuestActivo, no reclutando